Summary & Overview
CPT 0489T: Autologous Adipose-Derived Regenerative Cell Therapy for Scleroderma Hands
CPT code 0489T designates an autologous adipose-derived regenerative cell procedure for treatment of scleroderma in the hands, encompassing fat harvest, ex vivo processing to achieve a specified concentration/dilution of regenerative cells, and reinfusion. This emerging reconstructive and regenerative therapy has implications for specialty procedural billing, facility utilization, and coverage policy as payers evaluate clinical evidence for efficacy and safety. Nationally, attention centers on how commercial insurers and Medicare handle coverage, prior authorization, and reimbursement for combination services that span surgical, laboratory, and injection components. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of code intent and clinical context, payer coverage patterns and common modifiers observed, and benchmarks for site-of-service utilization and typical billing practice where available. The publication also summarizes policy developments and coding guidance relevant to regenerative cell therapies, clarifies common billing challenges for multi-step procedures, and highlights areas where data are limited. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 0489T describes an autologous adipose-derived regenerative cell procedure in which a provider harvests the patient’s own fat cells, processes them through concentration and dilution steps, and returns the regenerative cell preparation for treatment of scleroderma of the hands. The procedure involves tissue harvest, laboratory processing to obtain a specific concentration of regenerative cells, and re-injection to affected hand tissues.
-
Service type: Autologous adipose-derived regenerative cell therapy (harvest, processing, and reinfusion)
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting where liposuction and sterile cell processing and injection can be performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with localized scleroderma (systemic sclerosis with prominent hand involvement) who experiences painful digital ulcers, thickened skin, reduced hand range of motion, and impaired function despite optimized medical therapy. The multidisciplinary team includes a rheumatologist and a hand surgeon or plastic surgeon with experience in regenerative treatments. The patient presents to an ambulatory surgery center or outpatient procedure suite after pre-procedure evaluation confirms suitability for autologous adipose-derived cell therapy.
The clinical workflow: the patient receives informed consent and pre-procedure optimization, including assessment of coagulation status and medication reconciliation. In the procedure suite, tumescent liposuction is performed to harvest autologous adipose tissue (usually from the abdomen or flanks). The harvested fat is processed using mechanical and/or enzymatic methods per device/clinic protocol to concentrate regenerative cell populations and achieve a specified dilution/concentration. The processed adipose-derived regenerative cell suspension is then injected into affected areas of the hands (e.g., subcutaneous and peri-lesional injections around digital ulcerations and sclerotic bands) under sterile conditions, often with local or monitored anesthesia care. Post-procedure monitoring includes vital sign observation, wound care of the donor and injection sites, hand therapy referral as needed, and follow-up visits to assess pain, wound healing, range of motion, and adverse events.
Typical site of service: outpatient ambulatory surgery center or hospital outpatient department. Service type: autologous adipose-derived regenerative cell harvest, processing, and reimplantation for treatment of scleroderma of the hands. Typical patient scenario: adult with refractory scleroderma-related hand dysfunction and ischemic digital ulcers who has failed conventional medical and local wound therapies and is enrolled in clinic protocol or offered an off-label regenerative procedure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or intensity substantially exceeds usual for 0489T and documentation supports increased complexity. |
23 | Unusual anesthesia | Use when general anesthesia or deep sedation is required for the procedure that is normally performed with local anesthesia. |
51 | Multiple procedures | Use when 0489T is billed on the same day with other distinct procedural CPT codes; report primary procedure first per payer rules. |
52 | Reduced services | Use when the full service described by 0489T is partially reduced or not completed and documentation explains the reduction. |
53 | Discontinued procedure | Use when the procedure is started but terminated due to patient emergency or other documented circumstances before completion. |
62 | Two surgeons | Use when two surgeons of different specialties perform distinct portions of 0489T and documentation supports concurrent roles. |
66 | Surgical team | Use when a surgical team performs the procedure and payer allows team reporting; follow payer-specific guidance. |
78 | Unplanned return to OR | Use when a return to the operating room for a related procedure is required during the global period of 0489T. |
80 | Assistant surgeon | Use when an assistant surgeon provides medically necessary assistance during 0489T and payer accepts assistant surgeon claims. |
81 | Minimum assistant surgeon | Use when a minimum assistant is used and payer recognizes reduced assistant involvement. |
82 | Assistant not available | Use when a qualified assistant is not available and an alternative provider performs assistant tasks with documentation. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services furnished in part-time | Use when an advanced practice provider performs part or all of a service and payer accepts AS. |
QX | Registered dietitian/other? (Modifier QX used for lab certs) | Use when laboratory CLIA requirements apply to the processing of specimens and the laboratory or personnel meet modifier QX billing rules. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RC0000X | Plastic Surgery | Performs adipose harvest, processing oversight, and injections for hand reconstruction. |
| 207RH0000X | Hand Surgery | Specialized management of hand-specific injections, debridement, and functional outcomes. |
| 207RG0100X | General Surgery | May perform adipose harvest in ambulatory settings. |
| 2084P0800X | Rheumatology | Referring and co-managing physicians for scleroderma treatment and outcome assessment. |
| 207T00000X | Physical Medicine & Rehabilitation | Provides pre- and post-procedure hand therapy and functional rehabilitation. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M34.0 | Progressive systemic sclerosis | Primary systemic form of scleroderma that causes hand fibrosis and digital ischemia targeted by regenerative adipose therapy. |
M34.1 | CR(E)ST syndrome | Limited systemic sclerosis variant with prominent hand involvement, Raynaud phenomenon and digital ulcers. |
M34.81 | Other forms of systemic sclerosis with lung involvement | Systemic disease context where hand manifestations coexist and may be treated symptomatically with local regenerative therapy. |
L98.4 | Chronic ulcer of skin, not elsewhere classified | Represents chronic digital ulcerations of the hand that may be an indication for local regenerative therapy. |
M79.64 | Pain in left hand | Symptom code used to capture hand pain associated with scleroderma treated by 0489T. |
M79.65 | Pain in right hand | Symptom code used to capture unilateral hand pain associated with scleroderma. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
15771 | Dermal fat graft; single plane (separate procedure), includes obtaining graft | May be used for soft tissue augmentation in hand reconstruction and is related conceptually to adipose tissue transfer though technique differs from 0489T. |
20926 | Tissue grafts, other than autograft, includes obtaining graft (eg, dermal, fascial) | Occasionally used for soft tissue defect management in the hand alongside regenerative treatments; distinct from autologous cell processing in 0489T. |
01810 | Anesthesia for procedures on the fingers, including digital block | Often billed when regional or digital block anesthesia is used during hand injections associated with 0489T. |
0350T | Processing of harvested adipose tissue, with concentrated cells returned to patient | Represents processing steps analogous to those described in 0489T and may be used in facilities with discrete device-dependent processing codes. |
99024 | Postoperative follow-up visit, after surgery (global period) | Used for routine postoperative follow-up visits after 0489T when payers require separate reporting of postoperative care. |